Promomed's revenue in the first quarter increased by 62.2%

Promomed's revenue for 3 months of 2026 amounted to ₽7.3 billion, an increase of 62.2%, which is more than five times higher than the growth rate of the pharmaceutical market, which was 12% according to IQVIA. In the Endocrinology segment, revenue increased threefold to ₽4.8 billion. In the Oncology segment, sales decreased by 45% to ₽0.7 billion due to government purchases, which were concentrated in the second half of 2026. The shares of budget and commercial sales in revenue were 23% and 77%, respectively.